MiNK Therapeutics, Inc. (NASDAQ:INKT) Short Interest Up 303.4% in March

MiNK Therapeutics, Inc. (NASDAQ:INKT) was the recipient of a large growth in short interest in March. As of March 13th, there was short interest totaling 149,702 shares, a growth of 303.4% from the February 26th total of 37,106 shares. Currently, 4.1% of the shares of the stock are short sold. Based on an average daily volume of 1,570,416 shares, the short-interest ratio is currently 0.1 days. Based on an average daily volume of 1,570,416 shares, the short-interest ratio is currently 0.1 days. Currently, 4.1% of the shares of the stock are short sold.

MiNK Therapeutics Trading Down 2.9%

Shares of NASDAQ INKT opened at $8.56 on Wednesday. The business has a 50-day moving average of $11.13 and a 200-day moving average of $12.42. The firm has a market capitalization of $40.15 million, a price-to-earnings ratio of -2.83 and a beta of 0.35. MiNK Therapeutics has a 12 month low of $6.34 and a 12 month high of $76.00.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded MiNK Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, January 19th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, MiNK Therapeutics presently has an average rating of “Hold” and a consensus price target of $35.00.

Hedge Funds Weigh In On MiNK Therapeutics

A hedge fund recently bought a new stake in MiNK Therapeutics stock. DRW Securities LLC purchased a new position in MiNK Therapeutics, Inc. (NASDAQ:INKT) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 25,677 shares of the company’s stock, valued at approximately $286,000. DRW Securities LLC owned about 0.55% of MiNK Therapeutics as of its most recent SEC filing. 2.87% of the stock is owned by institutional investors.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.